The survival of Bifidobacterium animalis subsp. lactis OPB-1 in the gastrointestinal tract after its administration in a milk-free yogurt-like soybean product and effects on fecal microbiota in humans were determined. Twelve healthy volunteers were administered 100 g of yogurt-like soybean product for 3 weeks. The plate count method combined with specific PCR and quantitative real-time PCR were used to estimate the numbers of total Bifidobacterium and B. animalis subsp. lactis in fecal samples. B. animalis subsp. lactis was detected during the administration period but not before. The intake number of B. animalis subsp. lactis OPB-1 was 2.4 × 10 10 CFU/day by the plate count method and 4.2 × 10 13 copies/day by quantitative real-time PCR. However, the number of excreted B. animalis subsp. lactis per day was estimated to be more than 10 times the intake number, by both methods. The percentage of Bifidobacterium increased from 16.9 ± 21.8% to 34.1 ± 20.4% by the plate count method and 18.9 ± 13.4% to 27.8 ± 15.8% by the T-RFLP method after 3 weeks administration.
Introduction
Many bacteria live and form intestinal microbiota in the digestive tract of humans. The intestinal microbiota consists of more than 500 bacterial species and the number of bacteria is said to be 10 11 per g of wet feces (Ohashi, 2006) . The intestinal microbiota is believed to be closely related to host health (Mitsuoka, 1982) . Among these, bifidobacteria are major intestinal bacteria, comprising 75 − 91% of intestinal bacteria in the digestive tract of infants (Harmsen et al., 2000) and 3 − 7% of those of adults (Biavati and Mattarelli, 2001) . Bifidobacteria are believed to contribute to health maintenance in hosts. These findings have shed light on the use of food products containing certain species of bifidobacteria, such as fermented milk products, as probiotics. A probiotic is defined as a live microorganism that exerts a desirable effect on the host when an optimal amount is ingested (Fuller, 1991) . It has been reported that the ingestion of probiotics could be expected to improve the intestinal microflora (Fuller and Gibson, 1997) , aid in bowel movement (Mori et al., 2009) , heighten immune function (Yasui et al., 1992 , Yasui et al., 1995 , prevent pollinosis (Odamaki et al., 2007) , and ameliorate irritable bowel syndrome (O'Mahony et al., 2005) . However, many probiotics are milk-based products, which people with milk allergy cannot consume. In addition, vegans cannot consume these products. Furthermore, the ingestion of lactic acid bacteria and bifidobacteria from fermented milk and the like entails the ingestion of milk fat and cholesterol, which is not considered desirable for everyone. In recent years, soybean-based yogurt-like food products have been produced. However, milk components are often used for the production of lactic acid bacteria and bifidobacteria. There are few products that are completely free of milk components. Several reports exist on the delivery of lactic acid bacteria and bifidobacteria contained in fermented milk to the intestine, and the ameliorating effects on the intestinal microbiota. However, there is scant information on soybeanbased yogurt-like products free from milk components. Bifidobacterium animalis subsp. lactis is the best known probiotic, and is used in fermented milk (Biavati et al., 1992) and cal samples were collected from each subject before administration, at weeks 2 and 3 during the administration period, and at week 1 after administration. The study was approved by the local Ethic Committee of Emilio Moriguchi Clinic, and was conducted based on the principles of the World Medical Association Declaration of Helsinki (1964) , under the management and guidance of a physician. Informed consent was obtained from all subjects prior to the start of the study.
Examination of fecal samples and genus-and speciesspecific PCR The numbers of Bifidobacterium, Bacteroides, and total anaerobes were determined within 24 h of fecal sample collection, according to the method of Mitsuoka (1980) (Mitsuoka, 1980) and BBE agar (Becton Dickinson, Sparks, MD), respectively. BL agar (Eiken Chemical, Tochigi, Japan) and CDC agar (Becton Dickinson) were used for enumeration of total anaerobes. The plates were incubated at 35℃ for 3 − 5 days, in an anaerobic jar with an atmosphere of oxygen-free CO 2 using AnaeroPack-Anaero (Mitsubishi Gas Chemical, Tokyo, Japan). Bacterial densities were expressed as log CFU/g wet weight of feces. After incubation, 10 colonies from each BS agar plate were applied to genusand species-specific multiplex-PCR to distinguish B. animalis subsp. lactis from other Bifidobacterium, according to the procedure of Ventura et al. (2001) . (Salminen et al., 2005) . We prepared a yogurt-like soybean product free from milk components, using B. animalis subsp. lactis OPB-1 previously cultivated in milk-free media. The objectives of this study were to show that B. animalis subsp. lactis OPB-1 passes live through the digestive tract and to examine its effect on intestinal microbiota, as the first step in characterizing the benefits of milk-free yogurt-like soybean products. The behavior of B. animalis subsp. lactis in the digestive tract is also discussed.
Materials and Methods
Bacterial strains and yogurt-like soybean product (YSP) B. animalis subsp. lactis OPB-1 was provided by Sacco Inc. (Cadorago, Italy) as a concentrated frozen pellet (10 11 CFU/ g). This strain had been cultivated in a milk component-free medium, and was maintained at −80℃ before use. Pediococcus pentosaceus IDS885m4 was grown in carrot juice (Brix 6%) at 37℃ for 14 h, and stored at 5℃. YSP was prepared from whole soy milk containing soybean fiber, okara, as the main material, and fermented carrot juice containing P. pentosaceus IDS885m4, sugar, agar, flavor, citric acid and guar gum were used as ingredients. After the addition of B. animalis subsp. lactis OPB-1, the mixture was stored in a paper cup and refrigerated to 5℃. The nutrient content of YSP was as follows: energy 69 kcal/100 g, protein 3.3 g/100 g, lipid 2.1 g/100 g, carbohydrate 8.5 g/100 g, dietary fiber 1.5 g/100 g, Na 37 mg/100 g. The number of B. animalis subsp. lactis OPB-1 was 2.5 × 10 8 CFU/g (plate count method) and 4.0 × 10 11 copies/g (quantitative real-time PCR). YSP also contained 7.9 × 10 7 CFU/g of P. pentosaceus IDS885m4. The number of bacteria in YSP was stable at 5℃, 4 weeks after production. Subjects and study design Twelve healthy subjects, 5 women and 7 men, aged 25 − 60 years (mean age, 42.7 years) were selected for this study. The inclusion criteria were: no history of digestive pathology and no use of medications affecting the intestinal microbiota, such as antibiotics, antacids or laxative drug treatments. The subjects did not have a history of soy allergy or intolerance, nor did they exhibit other symptoms during the study. The study was divided into 3 periods: a wash out period (2 weeks), YSP administration period (3 weeks) and post-administration period (1 week). The amount of YSP administered was 100 g/ day. Throughout the study period, the subjects were asked to avoid fermented milk, oligosaccharides, kimchi, fermented soybean (natto) and any food or antibiotic that might influence the fecal microbiota, other than that used in the study. Besides these, there were no specific dietary restrictions. Fe-performed using Lm26/Bif228. Therefore, a correction factor "0.961" was used for calculation of total Bifidobacterium as follows: Total Bifidobacterium (copy/mg DNA) = Bifidobacterium genus (using Lm26/Bif228, copy/mg DNA) + 0.961·B. animalis subsp. lactis (using Bflact2/Bflact5, copy/ mg DNA).
T-RFLP Terminal restriction fragment length polymorphism (T-RFLP) was performed using the procedure of Nagashima et al. (2006) at TechnoSurga Laboratory (Shizuoka, Japan). In brief, frozen fecal specimens were suspended in GTC buffer (100 mM Tris-HCl buffer, pH 9.0, 40 mM Tris-EDTA buffer, pH 8.0, 4M guanidine thiocyanate). Fecal solids in the suspension were broken down using a FastPrep FP100A Instrument (MP Biomedicals, CA) with zirconia beads at 5 m/sec for 2 min. DNA was extracted from a 200 µL suspension using an automatic nucleic acid extractor (Precision System Science, Chiba, Japan). MagDEA DNA200(GC) (Precision Science) was used as the reagent for the automatic nucleic acid extraction. The PCR primer for 516F labeling was switched from HEX to FAM. PCR products were purified using a MultiScreen PCRμ96 plate (Millipore, MA). The resulting 16S rDNA amplicons were treated with 10U of BslI (New England BioLabs, MA) for 3 h. Fragment analysis was performed with a ABI PRISM 3130xl DNA Sequencer (Applied Biosystems, Carlsbad, CA) using the DNA analysis software Gene Mapper (Applied Biosystems). MapMarkerR, 50 − 1000 bp, X-Rhaodamine conjugate (BioVentures, Murfreesboro, TN) was used as the size standard marker. Bacterial flora was compared by hierarchical cluster analysis (GeneMaths; Applied Maths, Belgium) of the ratio of the peak area to the total area of each OTU bp amplicons with the primer set Lm3/P0 were detected from these Bifidobacterium strains without B. animalis subsp. lactis.
Quantitative real-time PCR Real-time PCR was used to quantify bifidobacteria and B. animalis subsp. lactis in fecal samples. Fecal material (0.1 g) was suspended in 0.9 mL of phosphate buffered saline, and 200 μL of the suspension was used for DNA extraction with Magtration System 12GC (Precision System Science, Chiba, Japan), following the manufacturer's instructions. Quantitative real-time PCR was performed using Rotor-Gene Q (Qiagen, Hilden, Germany). The reaction mixture (25 μL) was composed of 12.5 μL of SYBR:Premix Ex Taq (Takara Bio, Shiga, Japan), 0.2 μL of DNA extraction buffer, and 0.2 μM of each specific primer (Table 1 ). The amplification program used was as follows: preheating 95℃ for 30 sec, 35 cycles of denaturation at 94℃ for 5 sec, annealing at 64°C for 20 sec (for Bifidobacterium genus specific primer, Lm26/Bif228) or 58℃ for 45 sec (for B. animalis subsp. lactis specific primer, Bflact2/Bflact5) and extension at 72℃ for 90 sec. The quantities of target copies contained in an unknown sample were determined from the standard curve. The standard curve was constructed comparing the cycle threshold of each sample with the number of copies. B. longum JCM1217 and B. animalis subsp. lactis OPB-1 were used as standard DNA. The primer set (Lm26/ Bif228) was designed for Bifidobacterium genus from the intestinal tract. Therefore, a difference of 2 bases is recognized between the DNA sequence of forward primer (Lm26) and the 16S rDNA sequence of B. animalis subsp. lactis. However, amplicons were obtained with 3.9% of the copy number of B. animalis subsp. lactis OPB-1, when PCR was Survival of B. animalis subsp. lactis OPB-1 Ventura et al. (2001) administration period were 9.9 ± 0.5 log 10 CFU/g (p = 0.078) and 10.1 ± 0.6 log 10 CFU/g (p = 0.086) by the plate count method. Assessed using quantitative real-time PCR, the number of total Bifidobacterium increased significantly (P = 0.01) at week 2 and 3 of YSP administration; however, one week post-administration, the number decreased to the level before administration. The number of excreted B. animalis subsp. lactis OPB-1 per day was calculated using fecal bacterial numbers and average evacuation weight during the 2nd and 3rd week of YSP administration. During the administration period, the intake number of B. animalis subsp. lactis OPB-1 was 2.4 × 10 10 CFU/day by the plate count method and 4.2 × 10 13 copies/day by quantitative real-time PCR. On the other hand, the number of excreted B. animalis subsp. lactis OPB-1 was estimated as 3.2 × 10 11 CFU/day and 7.9 × 10 11 CFU/day by the plate count method combined with species-specific PCR and 7.9 × 10 14 copies/day and 9.7 × 10 14 copies/day by quantitative real-time PCR, at weeks 2 and 3 of the administration period, respectively (Fig. 1) .
Effect on fecal microbiota
The number of Bifidobacterium, Bacteroides and total anaerobic bacteria were analyzed before, during the 2 and 3 weeks of administration and one week post-administration of YSP. Relative abundance of Bifidobacterium and Bacteroides in total anaerobic bacteria is shown in Fig. 2 . In 10 cases of 12 subjects, relative abundance of Bifidobacterium increased and that of Bacteroides decreased in 11 of 12 subjects, at week 3 of YSP ingestion. Relative abundance of Bifidobacterium increased from 16.9 ± 21.8% to 21.8 ± 16.0% and 34.1 ± 20.4%, while relative abundance of Bacteroides decreased from 54.0 ± 21.4% to 33.8 ± 23.0% and 33.6 ± 17.9%, at weeks 2 and 3 of YSP (operational taxonomic unit).
Statistical analysis Bacterial numbers were converted to log colony forming units (CFU)/g wet weight and expressed as means ± SD (standard deviation). For the quantitative PCR, results were converted to log copy numbers/mg DNA extract. Results obtained at various time points were compared using a two tailed paired t-test. Calculations were performed using SPSS 19.0 software (SPSS Inc, Chicago, IL) and p < 0.05 was regarded as significant.
Results

Quantification of total Bifidobacterium and B. animalis subsp. lactis in feces Total
Bifidobacterium and B. animalis subsp. lactis of fecal samples were analyzed using the plate count method combined with genus-and speciesspecific PCR and quantitative real-time PCR, before, during and after ingestion of YSP. The results are shown in Table 2 . Before administration of YSP, B. animalis subsp. lactis was not detected in any of the subjects by the plate count method combined with species-specific PCR and quantitative realtime PCR. During 2 and 3 weeks of YSP administration, the plate count method combined with species-specific PCR detected cultivable B. animalis subsp. lactis in the feces of 11 of 12 healthy volunteers. The subjects in which B. animalis subsp. lactis was not detected at week 2 and 3 were not the same. Using quantitative PCR, B. animalis subsp. lactis was detected in all subjects during administration of YSP. One week post-administration, B. animalis subsp. lactis was not detected by the plate count method, and the number and detection rate of B. animalis subsp. lactis in feces tended to decrease, as assessed by quantitative real-time PCR. The number of total Bifidobacterium at week 2 and 3 during the 9.9 ± 0.5 (12/12) 10.1 ± 0.6 (12/12) 9.9 ± 0.4 (12/12) Quantitative PCR (copy/mg DNA) Bifidobacterium 11.3 ± 0.7 (12/12) 11.4 ± 0.5 (12/12) 11.6 ± 0.4 (12/12) 11.3 ± 0.7 (12/12) B. animalis subsp. lactis ND (0/12) 11.9 ± 0.6 (12/12) 12.2 ± 0.5 (12/12) 9.1 ± 1.0 (7/12) Total Bifidobacterium 11.3 ± 0.7 (12/12) 12.1 ± 0.4**(12/12) 12.3 ± 0.4**(12/12) 11.3 ± 0.7 (12/12) Mean±SD (standard deviation) ** Significantly higher than before administration (p < 0.01) 1) ND : not detected 2) Frequency of occurrence (no. of subjects yielding the organisms/no. of subjects examined) 3) One week after administration dobacterium increased from 18.9 ± 13.4% to 27.8 ± 15.8% (p < 0.05), and that of Bacteroides decreased from 8.2 ± 5.0% to 4.5 ± 3.3% (p < 0.08). This result is not contradictory to the result of the plate count method. No significant changes were detected in the other bacterial groups (Fig. 3) .
administration, respectively. However, one week post-administration, the frequency of Bifidobacterium decreased and the frequency of Bacteroides increased to initial levels Fecal microbiota was analyzed by the T-RFLP method, before and after 3 weeks of YSP ingestion. The ratio of BifiSurvival of B. animalis subsp. lactis OPB-1 Fig. 1 . The numbers of B. animalis subsp. lactis OPB-l ingested and excreted daily. The number of excreted B. animalis subsp. lactis OPB-l was calculated using fecal bacterial number and average evacuation weight during 2 nd and 3 rd week of YSP administration. Fig. 2 . Effect ofYSP ingestion on fecal microbiota during 2 and 3 weeks of administration and one week post YSP administration, according to the method of Mitsuoka (1980) . * Significantly higher than before ingestion (p < 0.05) Fig. 3 . Effect ofYSP ingestion on fecal microbiota in twelve subjects (T-RFLP). Fecal microbiota was analyzed by T-RFLP method, before and after 3 weeks ofYSP administration, according to the procedure of Nagashima et al. (2006) . * Significantly higher than before administration (p < 0.05) cates a favorable property as a probiotic.
The percentage of Bifidobacterium in the fecal microbiota and the number of total Bifidobacterium in feces increased during YSP administration. However, the number of Bifidobacterium, except for B. animalis subsp. lactis, did not show a remarkable change, as assessed using the plate count method combined with species-specific PCR and genus-specific quantitative real-time PCR, before, during and post administration ( Table 2 ). The relative abundance of Bifidobacterium, except B. animalis subsp. lactis, did not change by the T-RFLP method, before and at 3 weeks of YSP administration (data not shown). These results suggest that increments in the number and relative abundance of total Bifidobacterium were brought about by an increase of B. animalis subsp. lactis OPB-1. It was reported that ingestion of 2 − 6 g of soybean oligosaccharides increased Bifidobacterium in the human intestine (Tashiro, 2006) . YSP contained 0.4 g/100 g of stachyose and 0.08 g/100 g of raffinose, similar to commercial soymilk. In this study, the number of total Bifidobacterium increased by the ingestion of YSP; however, the number of Bifidobacterium, except B. animalis subsp. lactis OPB-1, did not remarkably change. The oligosaccharide content in YSP may not be sufficient to increase the population of indigenous Bifidobacterium. In addition, B. animalis subsp. lactis OPB-1 might compete with indigenous Bifidobacterium for utilization of oligosaccharides in the gastrointestinal tract. Kumemura et al. (2002) reported that administration of a cultured vegetable drink containing P. pentosaceus IDS885 altered the composition of fecal microflora in a beneficial manner for human health. P. pentosaceus IDS885 contained in YSP might affect the change in composition of fecal microbiota observed in this study.
One week post-administration, B. animalis subsp. lactis OPB-1 was not detected by the plate count method, and the number and detection rate of B. animalis subsp. lactis OPB-1 in feces tended to decrease, as assessed by quantitative realtime PCR (Table 1) . Therefore, this strain might not have a strong adhesive ability toward intestinal mucosal cells. It was reported that some human bifidobacterial strains show the ability to adhere to intestinal cells in vitro (Bernet et al., 1993 , Perez et al., 1998 . However, few reports show that ingested bifidobacteria colonize the human gut continuously for a long term (Bezkorovainy, 2001) . Kullen et al. (1997) fed a unique Bifidobacterium strain to human volunteers and then examined the fecal bifidobacterial flora. While the feeding continued, total bifidobacterial excretion increased; however, this strain disappeared from the feces after feeding was discontinued. From these results, they described that exogenous bifidobacteria can not colonize the gastrointestinal tract to a significant extent. Similar results were obtained by
Discussion
The present study examined the effect of ingestion of a milk-free yogurt-like soybean product containing B. animalis subsp. lactis OPB-1 on fecal microbiota by quantifying the number of viable B. animalis subsp. lactis OPB-1 excreted in the feces. Cultivation, molecular and biochemical approaches were applied to evaluate the recovery of B. animalis subsp. lactis OPB-1 and fluctuations in composition of gut microbiota in healthy adults before, during and after ingestion of 2.5 × 10 10 CFU/day of B. animalis subsp. lactis OPB-1 in YSP for 3 weeks. The combination of selective cultivation and speciesspecific PCR techniques allowed detection of cultivable B. animalis subsp. lactis in the feces of 11 of 12 healthy volunteers after 2 and 3 weeks of YSP ingestion (Table 2 ). Using quantitative real-time PCR, amplified DNA fragments corresponding to B. animalis subsp. lactis were detected in all subjects during YSP administration. Before administration of YSP, these amplified DNA fragments were not detected in all subjects. Therefore, the amplified DNA fragments corresponding to B. animalis subsp. lactis originated from the B. animalis subsp. lactis OPB-1 in YSP. Furthermore, the number of excreted B. animalis subsp. lactis OPB-1 per day was estimated to be more than 10 times the intake number (Fig. 3) . These results suggest that B. animalis subsp. lactis OPB-1 can survive passage through the gastrointestinal tract and proliferate in the digestive tract. Ishizuka et al. (2010) reported that B. animalis subsp. lactis GCL2505 present in fermented milk proliferated in the digestive tract. On the other hand, Rochet et al. (2008) observed survival rates of 20% or 22% for B. animalis subsp. lactis DN-173010 present in fermented milk or in lyophilized form in healthy subjects. Lactobacillus GG (Hosoda et al., 1994) , Lactobacillus plantarum ONC141 (Kumemura et al., 2001) and Pediococcus pentosaceus IDS885 (Kumemura et al., 2002) were reported to survive in the human intestinal tract. However, there are few reports detailing the proliferation in the digestive tract of these lactic acid bacteria. Acid tolerance and bile-acid tolerance of B. animalis subsp. lactis OPB-1 are higher than those of other Bifidobacterium species (data not shown). These properties of B. animalis subsp. lactis OPB-1 are probably the major factors by which B. animalis subsp. lactis OPB-1 survives and proliferates in the intestinal tract. Generally, it is thought that the population levels of probiotics must be sufficiently elevated to exert beneficial effects. Penna et al. (2000) described that the concentration of probiotics should be adjusted in the initial preparation to achieve a minimum of 10 7 CFU/g of intestinal content. The proliferation in the gastrointestinal tract of B. animalis subsp. lactis OPB-1 indi- Bouhnic et al. (1992) , and they concluded that administered Bifidobacterium spp. do not colonize the human colon. A pulsed-field gel electrophoresis (PFGE) analysis of fecal B. longum isolates of 12 human subjects revealed that each subject harbored strains of unique clones and most of them had persisted in the host intestine for over 68 weeks (Kohara et al., 2006) . In addition, PFGE profiles of these isolates were different from that of any B. longum commercially available. These results suggest that indigenous Bifidobacterium strains colonize all individuals' intestines. These findings lend credibility to the following notion: it may not be so important that the probiotic strains are isolated from human intestine and have strong adhesive ability to intestinal epithelium in vitro. If one assumes that increasing fecal bifidobacteria is the primary requisite for achieving probiotic effects, it seems important that we ingest a probiotic strain that can survive and proliferate continuously in the digestive tract.
In this study, we demonstrated that B. animalis subsp. lactis OPB-1 in a soybean product free of milk components can survive and proliferate in the gastrointestinal tract of healthy adults. Moreover, ingestion altered the composition of fecal microbiota in a manner that exerted a beneficial effect on human health. Yogurt-like soybean product that contains B. animalis subsp. lactis OPB-1 is a promising probiotic source for people wishing/needing to avoid milk components, and further research is expected in the future.
